• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The New England journal of medicine >Renal improvement in myeloma with bortezomib plus plasma exchange.
【24h】

Renal improvement in myeloma with bortezomib plus plasma exchange.

机译：骨髓瘤的肾改善与Bortezomib加等离子体交换。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is conflicting evidence on the benefit of plasma exchange to quickly reduce the level of serum free light chains and reverse acute renal failure associated with myeloma cast nephropathy.1"3 Such data are limited, since studies were conducted before the arrival of new agents, such as bortezomib, and serum assays for free light chains. The importance of renal function in the prognosis of patients with multiple myeloma has been well established, and rapid reversal of renal failure may offer the best long-term outcome.We reviewed our experience with a treatment strategy combining bortezomib-based therapy and plasma exchange in patients with biopsy-proven cast nephropathy or a high probability of cast nephropathy (defined as >200 mg per deciliter on the free light-chain assay). We did not include patients with transient renal failure that resolved promptly with hydration or correction of hypercalcemia in whom plasma exchange was not required.
机译：存在对血浆交换的益处有矛盾的证据，以迅速降低血清血清轻度链的水平和与骨髓瘤铸造肾病相关的逆向急性肾功能衰竭.1“3这样的数据是有限的，因为在新代理人到来之前进行研究， 如硼替佐米，以及用于游离灯链的血清测定。肾功能在多发性骨髓瘤患者预后的重要性已经确定，肾功能衰竭的快速逆转可能提供最佳的长期结果。我们审查了我们的经验 将硼佐螨的治疗和血浆交换结合在活组织检查验证的伴肾疗法患者中的治疗策略或浇注肾病的高概率（在游离轻链法测定上定义为每分列的> 200 mg）。我们不包括暂时的患者 不需要迅速解决的肾功能衰竭或纠正等质血症的矫正等离子体交换。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号